Peripheral Neuropathy Trial, Recruiting NCT05606068 Sponsor: National University Hospital, Singapore Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Peripheral Neuropathy Trial, Recruiting

NCT05606068
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between 21 and 80 years of age
  • People who have signed a consent form, or whose legal representative has signed on their behalf
  • People who are scheduled to receive weekly paclitaxel chemotherapy
  • People who are also receiving other chemotherapy drugs alongside paclitaxel, such as platinum-based drugs or Herceptin, may still be eligible

Who may not be able to join:

  • People who have open skin wounds or ulcers on their arms or legs
  • People who have a history of Raynaud's phenomenon (a condition affecting blood flow to the fingers and toes), peripheral vascular disease (poor circulation in the limbs), or diabetes that is not well controlled
  • People who are pregnant
  • People whose nerve function test (called a Total Neuropathy Score) shows a score higher than 5 at the start of the trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Rachel Wong, National University Hospital, Singapore

Phone: 6908 2222

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
National University Hospital, Singapore
Registry
ClinicalTrials.gov
Start date
11 November 2022
Est. completion
1 November 2026

Where this trial is recruiting

🇸🇬 Singapore

Primary endpoints

Incidence of Treatment-Emergent Adverse Events in cancer patients, over the duration of a limb cryocompression cycle, as assessed by Common Terminology Criteria for Adverse Events 5.0; Difference in qualitative symptom scores using the European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire-CIPN twenty-item scale

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov